Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia.
BTK inhibitors
Bruton’s tyrosine kinase
CXCR4
MyD88
Waldenström macroglobulinaemia
anti-CD20 monoclonal antibodies
drug resistance
lymphoplasmacytic lymphoma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
10
2021
accepted:
17
12
2021
entrez:
28
1
2022
pubmed:
29
1
2022
medline:
29
1
2022
Statut:
epublish
Résumé
Lymphoplasmacytic lymphoma (LPL) is a rare subtype of B cell-derived non-Hodgkin lymphoma characterized by the abnormal growth of transformed clonal lymphoplasmacytes and plasma cells. This tumor almost always displays the capability of secreting large amounts of monoclonal immunoglobulins (Ig) of the M class (Waldenström Macroglobulinemia, WM). The clinical manifestations of WM/LPL may range from an asymptomatic condition to a lymphoma-type disease or may be dominated by IgM paraprotein-related symptoms. Despite the substantial progresses achieved over the last years in the therapy of LPL/WM, this lymphoma is still almost invariably incurable and exhibits a propensity towards development of refractoriness to therapy. Patients who have progressive disease are often of difficult clinical management and novel effective treatments are eagerly awaited. In this review, we will describe the essential clinical and pathobiological features of LPL/WM. We will also analyze some key aspects about the current knowledge on the mechanisms of drug resistance in this disease, by concisely focusing on conventional drugs, monoclonal antibodies and novel agents, chiefly Bruton's Tyrosine Kinase (BTK) inhibitors. The implications of molecular lesions as predictors of response or as a warning for the development of therapy resistance will be highlighted.
Identifiants
pubmed: 35087759
doi: 10.3389/fonc.2021.801124
pmc: PMC8787211
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
801124Informations de copyright
Copyright © 2022 Piazza, Di Paolo, Scapinello, Manni, Trentin and Quintieri.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Oncol. 2020 Apr 10;38(11):1198-1208
pubmed: 32083995
Blood Cancer J. 2017 May 26;7(5):e565
pubmed: 28548645
Cancer Sci. 2006 Jan;97(1):72-9
pubmed: 16367924
J Clin Oncol. 2022 Jan 1;40(1):52-62
pubmed: 34606378
J Hematol Oncol. 2021 Mar 6;14(1):40
pubmed: 33676527
J Biol Chem. 2011 May 20;286(20):17682-92
pubmed: 21454712
J Biol Chem. 2009 Sep 11;284(37):25404-11
pubmed: 19592493
Blood Adv. 2019 Oct 8;3(19):2800-2803
pubmed: 31570491
Blood. 2014 Mar 13;123(11):1637-46
pubmed: 24366360
Hematol Oncol. 2021 Apr;39(2):215-221
pubmed: 33252145
Front Immunol. 2019 Feb 06;10:156
pubmed: 30787933
N Engl J Med. 2015 Apr 9;372(15):1430-40
pubmed: 25853747
PLoS Med. 2008 Mar 25;5(3):e64
pubmed: 18366248
Blood. 1997 Aug 1;90(3):1109-14
pubmed: 9242542
Br J Haematol. 2019 Nov;187(3):356-363
pubmed: 31267520
Hemasphere. 2021 Jul 19;5(8):e624
pubmed: 34291197
Schweiz Med Wochenschr. 1948 Sep 25;78(38):927
pubmed: 18885149
Ann Hematol. 1996 Mar;72(3):105-17
pubmed: 8766251
Leuk Lymphoma. 1997 Dec;28(1-2):23-31
pubmed: 9498700
J Clin Oncol. 2009 Mar 20;27(9):1492-501
pubmed: 19224851
Trends Biochem Sci. 2002 Sep;27(9):474-82
pubmed: 12217523
J Clin Oncol. 2003 Nov 1;21(21):3940-7
pubmed: 12975461
Br J Haematol. 2021 Aug;194(4):730-733
pubmed: 33713429
N Engl J Med. 2015 Aug 6;373(6):584-6
pubmed: 26244327
Leukemia. 2015 Jan;29(1):169-76
pubmed: 24912431
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80
pubmed: 20615965
Clin Cancer Res. 2021 Nov 1;27(21):5793-5800
pubmed: 34380643
Cancer Res. 2018 May 15;78(10):2457-2462
pubmed: 29703722
ChemMedChem. 2007 Jan;2(1):58-61
pubmed: 17154430
Br J Haematol. 2016 Aug;174(4):645-8
pubmed: 26523929
Blood. 2014 Jun 26;123(26):4120-31
pubmed: 24711662
Blood. 2020 Oct 29;136(18):2027-2037
pubmed: 32698195
Blood. 2016 Jun 23;127(25):3237-52
pubmed: 27143257
Best Pract Res Clin Haematol. 2016 Jun;29(2):169-178
pubmed: 27825463
Br J Haematol. 2016 Mar;172(5):735-44
pubmed: 26659815
Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):160-3
pubmed: 21454222
Am J Hematol. 2021 Dec 1;96(12):1569-1579
pubmed: 34462944
Immunity. 1997 Dec;7(6):837-47
pubmed: 9430229
J Med Chem. 2019 Sep 12;62(17):7923-7940
pubmed: 31381333
J Pharmacol Exp Ther. 2017 Nov;363(2):240-252
pubmed: 28882879
Best Pract Res Clin Haematol. 2016 Jun;29(2):241-248
pubmed: 27825470
Nature. 2011 Feb 3;470(7332):115-9
pubmed: 21179087
N Engl J Med. 2012 Aug 30;367(9):826-33
pubmed: 22931316
Blood Adv. 2020 Dec 8;4(23):6009-6018
pubmed: 33284944
Br J Haematol. 2020 Jun;189(6):1165-1170
pubmed: 32103491
Blood. 2018 May 3;131(18):2047-2059
pubmed: 29496671
Cancer Res. 2007 Nov 1;67(21):10556-63
pubmed: 17975000
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Clin Cancer Res. 2009 Apr 1;15(7):2523-30
pubmed: 19276251
Blood. 2020 Oct 29;136(18):2038-2050
pubmed: 32731259
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50
pubmed: 29982402
Clin Cancer Res. 2021 Oct 15;27(20):5492-5501
pubmed: 34253577
Blood. 2013 Aug 15;122(7):1222-32
pubmed: 23836557
Clin Cancer Res. 2008 Mar 1;14(5):1561-70
pubmed: 18316581
J Clin Oncol. 2018 Sep 20;36(27):2755-2761
pubmed: 30044692
Blood. 2017 May 4;129(18):2519-2525
pubmed: 28235842
Int J Mol Sci. 2020 Mar 18;21(6):
pubmed: 32197371
N Engl J Med. 2018 Jun 21;378(25):2399-2410
pubmed: 29856685
Leukemia. 2021 Sep 16;:
pubmed: 34531537
J Clin Oncol. 2021 Feb 20;39(6):565-575
pubmed: 32931398
Lancet Oncol. 2017 Feb;18(2):241-250
pubmed: 27956157
Exp Biol Med (Maywood). 2013 Sep;238(9):971-90
pubmed: 23986223
Haematologica. 2017 Jan;102(1):43-51
pubmed: 27758817
Lancet Haematol. 2020 Feb;7(2):e112-e121
pubmed: 31866281
Oncogene. 1990 Jul;5(7):1095-7
pubmed: 2374694
Best Pract Res Clin Haematol. 2011 Jun;24(2):203-16
pubmed: 21658619
Expert Rev Clin Immunol. 2019 Apr;15(4):383-389
pubmed: 30580638
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):372-379
pubmed: 33275726
N Engl J Med. 2013 Sep 26;369(13):1278-9
pubmed: 24066758
Am J Hematol. 2021 Feb 1;96(2):258-269
pubmed: 33368476
Blood. 2009 Apr 30;113(18):4163-70
pubmed: 19196866
Eur J Immunol. 2005 Jul;35(7):2175-83
pubmed: 15971270